Pay in 4 interest-free payments of $5.10 Learn more
Ships within 48 hours · Estimated delivery Nov 7 - Nov 12
Neurobiology of Aging
The gap between the volume of anecdote and the volume of human evidence is real
While the short-term benefits may seem appealing, the long-term risks are too significant to ignoreespecially when safer, better-understood alternatives are available
As a once-daily oral pill, orforglipron might be an attractive option for patients that choose orlistat over GLP-1 jabs
The result is a manufacturing process grounded in fermentation expertise and long-standing technical discipline
As Hemmi notes: Some people will lose access. In an emailed statement to WIRED, a spokesperson for Novo Nordisk says, Moving forward, any compounder that mass produces or sells knockoff drugs is breaking the law and compromising patient safety. A spokesperson for Eli Lilly echoed that sentiment, saying via email that the FDA and a federal court have both made clear that compounders must cease production of compounded tirzepatide knockoffs. Anthony Comuzzie, CEO of the Obesity Society, recognizes that there are legitimate access issues to GLP-1 medications, but he worries that some people who have sought out compounded versions may not meet the medical definition of obesity and are using them more casually for weight loss
